- ABSTRACT OF SERNOVA’S COLLABORATION WITH EVOTEC ON IPSC AND CELL POUCH™ COMBINATION TREATMENT DATA FOR TYPE ONE DIABETES SELECTED FOR ORAL PODIUM PRESENTATION
- FIRST PRE-CLINICAL DATA PRESENTATION OF SERNOVA’S CELL POUCH WITH EVOTEC’S IPSC DERIVED ISLET-LIKE CLUSTER TECHNOLOGY FOR TYPE 1 DIABETES (T1D)
London, ON, Canada, 14 March 2023:
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an oral presentation at the 4th International Pancreas and Islet Transplant Association (IPITA) / Harvard Stem Cell Institute (HSCI) / Juvenile Diabetes Research Fund (JDRF) Summit, to be held from April 24-25, 2023 in Cambridge, Massachusetts. The presentation will be given by Matthias Austen, PhD, SVP Cell Therapy at Evotec SE (FSE: EVT; NASDAQ: EVO).
Abstract Title: Manufacturing of optimized human islet-like clusters (ILCs) from iPSCs and functional testing of an ILC + Cell Pouch™ combination in vivo
Authors: Audrey Holtzinger, Simone Strauch, Thomas Reinbothe, Claudia Wrzos, Andreas Scheel, Cord Dohrmann, Arash Memarnejadian, Pardis Pakshir, Philip M. Toleikis, Matthias Austen
Date / Time: Monday, April 24, 2023 from 2:45pm-4:25pm ET
Evotec has developed a scalable and comprehensive process for GMP manufacturing of ILCs from a human GMP-grade induced pluripotent stem cell (iPSC) line for cell therapy in human insulin-dependent diabetes. In 2022, Evotec entered into a collaboration with Sernova Corp., which has developed the proprietary Cell Pouch System™. Following implantation, the Cell Pouch develops a vascularized environment to support engraftment and long-term function of therapeutic cells.
Sernova will disclose additional information about the presentation at the time of the conference.
For further information, please follow this link to the full version of the press release from Sernova.